Nonalcoholic steatohepatitis (NASH) is liver inflammation and damage caused by a buildup of fat in the liver. It is part of a group of conditions called nonalcoholic fatty liver disease. Non-alcoholic fatty liver disease (NAFLD) is one of the causes of fatty liver, occurring when fat is deposited (steatosis) in the liver due to causes other than excessive alcohol use. The more severe form of NAFLD is called non-alcoholic steatohepatitis (NASH). NAFLD spans a spectrum of clinicopathologic entities from simple hepatic steatosis to nonalcoholic steatohepatitis, cirrhosis, and hepatocellular carcinoma. Nearly 10% to 20% of the general population affected by NAFLD suffers from NASH. Therefore, the diagnosis methods for NAFLD helps in the prediction of NASH occurrence. In the United States, NASH-associated cirrhosis is currently the third most frequent reason for liver transplantation and is predicted to become the leading cause and it is projected to overtake Hepatitis C as the leading cause of liver transplants in the U.S. by 2020.
No medicines have been approved to treat NAFLD and NASH, however, some studies suggest that pioglitazone (Actos), a medicine for type 2 diabetes, improves NASH in patients without diabetes. Lifestyle changes are encouraged for patients with NASH, including reducing body weight, following a balanced diet, increasing physical activity, and avoiding alcohol. The NASH therapies in clinical pipeline (phase II and III) include Aramchol, ARI 3037MO, BMS-986036, Cenicriviroc (TBR-652), Elafibranor (GF-505), Emricasan (IDN-6556), GR-MD-02, GS-4997, Liraglutide (Victoza/Saxenda), Obeticholic acid (OCA/Ocaliva), Simtuzumab (GS-6624), Tipelukast, and Volixibat (SHP 626).
The global nonalcoholic steatohepatitis treatment market report provides market size (Revenue US$ Million 2014 to 2025), market share, market trends and forecasts growth trends (CAGR%, 2017 to 2025).
The global nonalcoholic steatohepatitis treatment market segmentation is based on drug type (Pioglitazone and Type 2 Diabetes Mellitus (T2DM) Medicines, Vitamin E, others), pipeline analysis (phase III drugs – Aramchol (Arachidyl Amido Cholanoic Acid), Elafibranor (GFT505), Emricasan (IDN-6556, PF-03491390), Obeticholic Acid (OCA/Ocaliva), Simtuzumab (GS-6624), others), and phase I and II drugs.
The global nonalcoholic steatohepatitis treatment market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global nonalcoholic steatohepatitis treatment market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global nonalcoholic steatohepatitis treatment market and included in this report are AstraZeneca plc, Conatus Pharmaceuticals, Galmed Pharmaceuticals, Genfit Sa, Gilead Sciences Inc., Immuron Ltd., Intercept Pharmaceuticals, Inc., Novartis, Pfizer, Tobira Therapeutics, Inc., and Zydus Cadila.